Related Experiment Videos
Clinical and molecular aspects of multiple endocrine neoplasia
1Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA.
Abstract:
The discovery that RET proto-oncogene mutations are responsible for MEN2 and FMTC was a landmark from the perspective of many, including the geneticist involved in basic science, the molecular diagnostician, the clinician, and MEN2/FMTC families. The discovery has provided basic information concerning the role of proto-oncogenes and proto-oncogene activation. The identification of MEN2/FMTC-associated mutations has also allowed for the availability of direct mutation analysis in the routine clinical laboratory. The discovery has resulted in definitive risk assessment for members of FMTC/MEN2 kindreds and improved management of RET mutation carriers. The discovery also links two realms of genetics that are often separated: cancer genetics and "classic" mendelian disorders. Finally, information concerning the molecular basis of Hirschsprung disease indicates that our understanding of the phenotypic consequences of RET mutations is considerable but not yet complete.
Insights
RET proto-oncogene mutations cause MEN2 and FMTC, enabling direct genetic testing for improved risk assessment and management. This discovery bridges cancer genetics and Mendelian disorders, with ongoing research into RET mutations and Hirschsprung disease.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Multiple Endocrine Neoplasia type 2 (MEN2) and Familial Medullary Thyroid Carcinoma (FMTC) are hereditary conditions.
- RET proto-oncogene mutations were identified as the underlying cause of MEN2 and FMTC.
Purpose of the Study:
- To highlight the significance of RET proto-oncogene mutations in MEN2 and FMTC.
- To discuss the impact of this discovery on genetic testing, risk assessment, and clinical management.
- To explore the connection between cancer genetics and Mendelian disorders.
Main Methods:
- Review of scientific literature and clinical findings related to RET proto-oncogene.
- Analysis of the role of RET mutations in MEN2, FMTC, and Hirschsprung disease.
- Discussion of the implications for molecular diagnostics and genetic counseling.
Main Results:
- RET proto-oncogene mutations are definitively linked to MEN2 and FMTC.
- Direct mutation analysis is now available for clinical diagnosis and risk assessment.
- The discovery facilitates a better understanding of proto-oncogene activation and its role in disease.
- A connection between cancer genetics and classic Mendelian disorders has been established.
Conclusions:
- The identification of RET mutations has revolutionized the diagnosis and management of MEN2 and FMTC.
- This breakthrough provides critical insights into hereditary cancer syndromes and genetic disorders.
- Further research into RET mutations is ongoing, particularly concerning Hirschsprung disease.